I-Corps: Personalized Tissue Engineering

I-Corps：个性化组织工程

• 批准号: 1753753
• 负责人: Sherry Harbin
• 金额: $ 5万
• 依托单位: Purdue University
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2018
• 资助国家: 美国
• 起止时间: 2018-01-01 至 2019-01-31
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=1753753&HistoricalAwards=false
• 关键词: Corps; Personalized; Tissue; Engineering

The broader impact/commercial potential of this I-Corps project is the potential commercialization of a platform technology for tissue engineering and regenerative medicine. Complex tissue injuries and non-healing wounds represent a global therapeutic challenge, making tissue engineering and regenerative medicine a multi-billion commercial opportunity with many unmet clinical needs. Today most wound care products rely on a "degrade and replace" mechanism, mediated by inflammation and resulting in disorganized scar tissue. The innovative technology, on which this project is based, works by a mechanism of "persist and regenerate" to restore tissue architecture and function. Additionally, these materials have unique capacity for customization, positioning it for future applications in areas including soft tissue reconstruction such as after tumor removal; repair of tendons, ligaments, and bone; tissue bulking agents for treating urinary incontinence or laryngeal paralysis; and for cellular therapies such as islet transplantation for diabetes. Taken together, these attributes will potentially enable innovative, low-cost products for personalized tissue engineering that have potential to reduce health care costs and improve patient outcomes.This I-Corps project is based on an advanced tissue-derived product, namely Collymer Self-Assembly Matrix, which represents the first injectable collagen which exhibits self-assembly-the ability to transition from a fluid to a stable fibrillar scaffold upon injection. This technology was inspired by new mechanistic insights into i) collagen synthesis and assembly as occurs within the body and ii) mechanobiology signaling which relies on cell-collagen biophysical interactions. Because Collymers immediately restore the natural tissue architecture by forming collagen fibrils just like those found in the body, this natural biomaterial is non-inflammatory and exhibits superior tissue regeneration. Collymers' unique capacity for patient-specific customization by incorporating cells and customizing the architecture of the scaffold (density, shape, and architecture) makes it the first personalized tissue regeneration/engineering technology. The specific aims of the I-Corps project is to explore and prioritize most promising applications for this technology as well as the best path to commercialization considering factors such as reimbursement, regulatory path and customer segment.

这个I-Corps项目更广泛的影响/商业潜力是组织工程和再生医学平台技术的潜在商业化。复杂的组织损伤和不愈合的伤口代表了全球性的治疗挑战，使组织工程和再生医学成为一个数十亿的商业机会，有许多未满足的临床需求。 今天，大多数伤口护理产品依赖于“降解和替换”机制，由炎症介导并导致疤痕组织紊乱。该项目所基于的创新技术通过“持续和再生”机制来恢复组织结构和功能。此外，这些材料具有独特的定制能力，将其定位于未来的应用领域，包括软组织重建，如肿瘤切除后;肌腱，韧带和骨骼的修复;用于治疗尿失禁或喉麻痹的组织填充剂;以及用于细胞治疗，如糖尿病的胰岛移植。综合考虑，这些属性将有可能使创新，低成本的个性化组织工程产品，有可能降低医疗保健成本和改善患者的结果。这个I-Corps项目是基于先进的组织衍生产品，即Collymer自组装矩阵，其代表了第一种表现出自组装的可注射胶原-在注射时从流体转变为稳定的纤维状支架的能力。该技术的灵感来自于对i）体内发生的胶原蛋白合成和组装以及ii）依赖于细胞-胶原蛋白生物物理相互作用的机械生物学信号的新的机械见解。由于Collymers通过形成与体内发现的胶原纤维一样的胶原纤维立即恢复天然组织结构，因此这种天然生物材料是非炎症性的，并且表现出上级组织再生。Collymers通过整合细胞和定制支架结构（密度、形状和结构）进行患者特定定制的独特能力使其成为第一个个性化组织再生/工程技术。I-Corps项目的具体目标是探索和优先考虑这项技术最有前途的应用，以及考虑报销、监管路径和客户群等因素的商业化最佳途径。